Takeda partners with an upstart drugs-from-bugs microbiome player inspired by a fecal transplantation biz
Back when Mark Smith was working on his PhD at MIT about 6 years ago, his girlfriend’s cousin was infected with C.diff. After 7 reoccurrences following treatment with vancomycin, though, the cousin finally beat it by getting a fecal transplant, with his roommate as the donor.
That incident both intrigued him and inspired Smith’s first jump into a startup, OpenBiome, which uses screened fecal samples for a more systematic approach in creating a safe, reliable supply of transplants to a growing market.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
